Todos Medical

Meet The Company Developing Advanved Blood Tests To Detect Cancer And Other Diseases

Todos Medical Receives New FDA Certificate of Free Sale for Tollovid® Max Strength including 5 Day Dosing, 30 Day Dosing And 3CL Protease (3CLpro, Mpro, Nsp5) Inhibitor Claim

Todos Medical Initiates IRB-Waived Tollovid® Market Research Study And Announces 50% Price Reduction Until May 30th, 2022

Todos Medical Receives New FDA Certificate of Free Sale for Tollovid® Max Strength including 5 Day Dosing, 30 Day Dosing And 3CL Protease (3CLpro, Mpro, Nsp5) Inhibitor Claim

Todos Medical Initiates IRB-Waived Tollovid® Market Research Study And Announces 50% Price Reduction Until May 30th, 2022

Todos Medical To Present At The Emerging Growth Conference

Todos Medical Appoints Philippe Goix As Chief Commercial Officer For Provista Diagnostics

Todos Medical To Present At The Emerging Growth Conference

Todos Medical Appoints Philippe Goix As Chief Commercial Officer For Provista Diagnostics

Todos Medical Reports 2nd Long COVID Case Study And Launches Website For Physicians And Pediatricians To Indicate Interest In Participating In Tollovid® Long COVID Clinical Study

Todos Medical Targets Athlete Support with Informed Sport Certification for Tollovid® by LGC Group

Todos Medical Recent News

New Study Reportedly Calls Into Question Merck's Ivermectin COVID Off Label Use And May Bolster 3CL Protease Inhibitors Such As Tollovid

This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice.

Todos Medical Applauds White House Initiative on Long COVID and Announces New Tollovid® US FDA Certificate Of Free Sale With Daily And Acute Dosing On The Label

New York, NY, and Tel Aviv, ISRAEL – April 6, 2022 - Todos Medical, Ltd. (OTCQB: TOMDF), a comprehensive medical diagnostics and related solutions company, today announced that its majority-owned subsidiary 3CL Pharma, Ltd.

Todos Medical Announces Positive 3CL Protease Inhibition In Vitro Data Against BA.1 and BA.2 Omicron SARS-CoV-2 Variants

New York, NY, and Tel Aviv, ISRAEL – April 4, 2022 - Todos Medical, Ltd.

UPDATE: Todos Medical Reports Fourth-Quarter And Full-Year 2021 Financial Results And Corporate Updates

New York, NY, and Tel Aviv, ISRAEL – April 1, 2022 - Todos Medical, Ltd.

Todos Medical Reports Fourth-Quarter And Full-Year 2021 Financial Results And Corporate Updates

New York, NY, and Tel Aviv, ISRAEL – April 1, 2022 - Todos Medical, Ltd.

Todos Medical Reports Case Study Of Patient With Long COVID

New York, NY, and Tel Aviv, ISRAEL, March 31, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- Todos Medical, Ltd.

Billy Blanks® Endorses Todos Medical's Line Of Tollovid® Products

New York, NY, and Tel Aviv, ISRAEL – March 27, 2022 - Todos Medical, Ltd.

Todos Medical To Present At The Proactive One2One Virtual Forum

- Thursday, March 17, 2022 at 2:00PM – 2:30PM ET -

Todos Medical Acquires Lucrative NLC Assets For Pennies On The Dollar

This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice.

Todos Medical Completes Acquisition Of Key Assets And Intellectual Property From NLC Pharma

- Forms new subsidiary, 3CL Pharma, focused on the development and commercialization of 3CL protease-related products including Tollovir™, Tollovid®, Tollovid Daily™ and TolloTest™ for COVID-19 -

Todos Medical To Present At The Emerging Growth Conference

- Wednesday, March 16, 2022 at 1:30 pm – 2 pm EST -

Todos Medical Appoints Greg Meiselbach As Vice President Of Government Affairs

New York, NY, and Tel Aviv, ISRAEL – March 8, 2022 - Todos Medical, Ltd. (OTCQB: TOMDF), a comprehensive medical diagnostics and related solutions company,

Abbott Labs Outlook Cools the Omicron Led Testing Boom

Photo by Adam Nieścioruk on Unsplash

Todos Medical and NLC Pharma Announce Primary and Secondary Endpoints Met in NLC-V-01 Phase 2 Clinical Trial of Oral Antiviral 3CL Protease Inhibitor Tollovir™ in the Treatment of Hospitalized COVID-19 Patients

Phase 2 Study NLC-V-01 closed early after interim data analysis due to positive clinical efficacy

Todos Medical Announces Data Lock in Tollovir™ Phase 2 Clinical Trial for the Treatment of Hospitalized COVID-19 Patients

Clinical Data will be released Thursday, January 27th, 2022

PEPPERDINE UNIVERSITY HOSTS THE 22ND ANNUAL CELEBRITY FLAG FOOTBALL CHALLENGE®, PRESENTED BY TODOS MEDICAL'S TOLLOVID®

In support of First Responders, Military Service Members and Boys and Girls Youth Groups

Todos Medical Releases Videos of Recent CEO Interviews with Fox Business, NewsMax and Black News Channel on COVID Testing & Treatment Strategies

New York, NY, and Tel Aviv, ISRAEL – January 18, 2022 - Todos Medical, Ltd.

Todos Medical to Announce Topline Results from Tollovir™ Phase 2 Clinical Trial from the Treatment of Hospitalized COVID-19 Patients on January 27th, 2022

Todos Medical CEO to Appear on Fox Business to Talk COVID Testing & Tollovir™ on Tuesday, January 11, 2022 and is Presenting at Biotech Showcase 2022

“COVID Testing: What Needs to Happen Now to Turn the Corner in 2022” CEO blog released

Todos Medical to Present at January 5, 2022 Emerging Growth Conference

New York, NY, and Tel Aviv, ISRAEL – January 3, 2021 - Todos Medical, Ltd.

Two Paths to End the Pandemic but the Hybrid Approach Looks Dominant

Pfizer (NYSE: PFE) is arguably one of the biggest leaders in COVID-19 technology, whether it’s their vaccine or their newly approved oral antiviral called P

Todos Medical CEO to Appear on Yahoo Finance Live! at 12:10PM EST with Akiko Fujita to Talk Pfizer's Paxlovid Approval, Tollovir™ Phase 2 & COVID Testing

CEO Gerald Commissiong is also scheduled to appear on BNC at 1:50PM EST to discuss the authorization of Pfizer’s COVID antiviral drug & Tollovir™ Phase 2 for hospitalized COVID

Todos Medical Announces New cPass Neutralizing Antibody Testing Reference Lab Agreement for CLIA/CAP Lab Provista with Physician Group in 40 States

Provista completed validation for fingerprick At-Home sample collection of blood for the cPass neutralizing antibody test